Advertisement

Search Results

Advertisement



Your search for Blood matches 4802 pages

Showing 251 - 300


hematologic malignancies

Studies Point to the Role of Diet in Hematologic Malignancies

According to research reported at the 2024 American Society of Hematology (ASH) Annual Meeting & Exposition, a link seems to exist between hematologic malignancies and dietary components. The speakers said their studies may ultimately lead to dietary interventions that could alter the course of ...

hematologic malignancies
leukemia
genomics/genetics

Study Finds Genetic Changes, Elevated Leukemia Risk in Ground Zero First Responders

First responders who worked at Ground Zero in the aftermath of the 2001 attacks on the World Trade Center in New York City were three times more likely to have genetic changes associated with an increased risk of leukemia compared with other first responders or members of the public who were not...

prostate cancer
issues in oncology

MRI-First Strategy May Be Safe for Prostate Cancer Detection

Researchers have examined whether a magnetic resonance imaging (MRI)-first approach is safe for prostate cancer detection over the long term, according to a recent study published by Hamm et al in JAMA Oncology. Background Several strategies may be deployed for the early detection of prostate...

hematologic malignancies
leukemia

Epcoritamab Monotherapy for Pretreated Relapsed or Refractory CLL

At the 2024 American Society of Hematology (ASH) Annual Meeting & Exposition (Abstract 883), Alexey Danilov, MD, PhD, of the Department of Hematology & Hematopoietic Cell Transplantation at City of Hope National Medical Center, Duarte, California, reported that single-agent epcoritamab led...

immunotherapy

Mesenchymal Cell Therapy Approved for Steroid-Refractory Acute GVHD

The U.S. Food and Drug Administration (FDA) recently approved remestemcel-L-rknd (Ryoncil), an allogeneic bone marrow–derived mesenchymal stromal cell therapy for steroid-refractory acute graft-vs-host disease (GVHD) in pediatric patients 2 months of age and older. The application received Orphan...

hematologic malignancies
leukemia
lymphoma
immunotherapy
issues in oncology

Researchers May Have Uncovered Protein That Helps Cancer Cells Dodge CAR T-Cell Therapy

Researchers may have discovered a factor contributing to cancer cell evasion of chimeric antigen receptor (CAR) T-cell therapy, according to a recent study published by Chen et al in Cell. The findings could lead to more personalized therapies that improve survival among patients with cancer....

supportive care

Managing Comorbidities in Oncology: Practical Strategies for Optimized Patient Care

Cancer care is increasingly complicated by the presence of comorbidities, which affect nearly two-thirds of patients at the time of diagnosis and can influence treatment decisions, participation in clinical trials, and overall outcomes. During 2024 JADPRO Live, M. Edie Brucker, DNP, MPH, ARNP,...

breast cancer

Learning From the ZEST Trial in Using ctDNA to Predict Breast Cancer Recurrence

The phase III ZEST clinical trial, designed to evaluate the PARP inhibitor niraparib for the prevention of breast cancer recurrence in patients with circulating tumor DNA (ctDNA), failed to accrue enough patients positive for ctDNA, according to results presented at the 2024 San Antonio Breast...

lymphoma
issues in oncology

Autologous Stem Cell Transplantation May Not Improve Survival in Patients With MCL and Undetectable Minimal Residual Disease

Researchers have revealed that high-dose chemotherapy followed by autologous stem cell transplantation may not benefit patients with mantle cell lymphoma (MCL) who are in remission following initial treatment, according to new findings presented by Fenske et al at the 2024 American Society of...

leukemia
issues in oncology

Combination of Two Oral Agents May Improve Progression-Free Survival in Patients With Previously Untreated CLL

A combination of the oral drugs acalabrutinib and venetoclax may be more effective at improving progression-free survival and minimizing serious adverse events in patients with previously untreated chronic lymphocytic leukemia (CLL) compared with one of two standard multidrug treatment regimens,...

multiple myeloma

High-Fiber Diet May Slow Disease Progression to Multiple Myeloma

Recent data suggest that a plant-based diet rich in fiber may help to improve the outlook for people with precursor conditions that can lead to multiple myeloma. The research, which involved a 12-week controlled diet with additional health coaching for 20 patients as well as experiments in mice, is ...

symptom management
supportive care

Rilzabrutinib Found Safe and Effective for Refractory Immune Thrombocytopenia

The experimental drug rilzabrutinib was well tolerated and generated an increase in platelet counts among some adults with immune thrombocytopenia (ITP) who had not experienced lasting improvements with other available ITP treatments, according to the results of a phase III trial. These findings...

lymphoma
immunotherapy

Preclinical Findings Show Ketogenic Diet Enhances CAR T-Cell Function, Improves Tumor Control

Findings from a series of studies conducted in mice, human tissues, and healthy volunteers suggest that a ketogenic diet may enhance the effectiveness of chimeric antigen receptor (CAR) T-cell therapy. The results point to β-hydroxybutyrate (BHB), a substance produced when a ketogenic diet is...

multiple myeloma

Will CAR T-Cell Therapy Be the Magic Bullet for My Multiple Myeloma?

Intense pain on the right side of my lower rib cage, in 2020, sent me first to my chiropractor for relief and then to my primary care provider for tests. Because of the location of the pain, the chiropractor thought I might be having a gallbladder attack, but the results from a urine test showed a ...

pancreatic cancer
colorectal cancer
multiple myeloma
bladder cancer
solid tumors

The Future of Cancer Care, Part 2

The soaring number of cancer survivors since the National Cancer Act of 1971 was enacted into law provides a snapshot of the profound progress made against cancer over the past half-century: 3 million survivors in the 1970s,1 compared to more than 18 million today, and that number is expected to...

hematologic malignancies

ASH Announces Recipients of 2024 ASH Advocacy Awards

The American Society of Hematology (ASH) honored Rep. Michael Burgess, MD (R-TX) and Centers for Disease Control and Prevention (CDC) health scientist Mary Hulihan, DrPH, for their leadership on issues of importance to hematology research and practice at the 2024 ASH Annual Meeting &...

hematologic malignancies

Understanding the Assessment and Treatment of High-Risk Myelofibrosis

At the 2024 JADPRO Live event, which is held annually for advanced practitioners in oncology, high-risk myelofibrosis was a featured topic. “The treatment landscape has developed so much that JADPRO asked us to present our talks on the main stage this year,” said Julie Huynh-Lu, PA-C, Supervisor...

gynecologic cancers
cardio-oncology

Prophylactic Surgical Menopause for Women With Familial Risk of Ovarian Cancer: Impact on Coronary Artery Calcium Development

The results of the HARMOny study published in JACC: CardioOncology by Beekman et al did not reveal a long-term adverse effect of prophylactic surgical menopause on the development of coronary artery calcium—a marker of cardiovascular disease risk—in women with a high familial risk of ovarian...

issues in oncology

Understanding the Link Between Obesity and Cancer

Worldwide, more than a billion people have obesity—including 650 million adults, 340 million adolescents, and 39 million children1—a rate that has nearly doubled since 1980.2 In the United States alone, about two out of three adults are overweight or have obesity, and one out of three have...

lung cancer

Toripalimab Plus Chemotherapy in First-Line Therapy for Extensive-Stage Small Cell Lung Cancer

In a Chinese phase III trial (EXTENTORCH) reported in JAMA Oncology, Cheng et al reported that the addition of the immunoglobulin G4 PD-1–blocking antibody toripalimab to first-line chemotherapy with etoposide plus cisplatin or carboplatin (EP) improved progression-free survival among patients with ...

issues in oncology

Could SARS–CoV-2 Be an Oncogenic Agent and Cancer Initiator?

It’s not news that some viruses, including human papillomavirus, human immunodeficiency virus, Epstein-Barr, and hepatitis B, can cause or accelerate the development of cancer. But a recent story in The Washington Post about rare cancers being diagnosed in individuals who had previously been...

multiple myeloma

Daratumumab Induction Regimen in Transplant-Ineligible Patients Newly Diagnosed with Multiple Myeloma

In the phase III CEPHEUS trial,1 the achievement of undetectable measurable residual disease (or MRD negativity)—the primary endpoint—was met by 61% of patients with transplant-ineligible or deferred newly diagnosed multiple myeloma treated with the monoclonal antibody daratumumab plus bortezomib, ...

leukemia

Obecabtagene Autoleucel in Adults With B-Cell ALL

A second-generation chimeric antigen receptor (CAR) T-cell therapy may offer a new option for patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL), an aggressive blood cancer with few treatment options. Results from the phase Ib/II FELIX trial, published by Roddie et al in ...

cardio-oncology

Evidence-Based Recommendations and Knowledge Gaps Regarding Cardio-Oncology

A recent report highlighted evidence-based recommendations for the prevention, detection, and management of cancer therapy–related cardiovascular toxicity and cardiovascular events in patients with cancer, as well as knowledge gaps. Select considerations are summarized herein. “The European Society ...

colorectal cancer
issues in oncology

At-Home Testing Kits, Coordinated Outreach May Improve Colorectal Cancer Screening Rates

Researchers have demonstrated that a targeted intervention may increase screening rates in patients who do not adhere to current colorectal cancer screening recommendations, according to a recent study published by Reuland et al in JAMA Network Open. Background Colorectal cancer screening is often...

bladder cancer

Cancer Has Plagued My Family

My twin brother and I were adopted at 18 months old, so I don’t know the medical history of our biological parents and family. But for certain, cancer has played an integral—and heartbreaking—role in my life. Both of my adoptive parents were diagnosed with genitourinary cancers at relatively early ...

hematologic malignancies
issues in oncology

Impact of ASH Minority Recruitment Initiative on Retaining, Engaging Underrepresented Hematologists

Participants of the American Society of Hematology (ASH) Minority Recruitment Initiative had lower attrition rates in graduate and medical programs, were more likely to pursue a career in hematology, and had high levels of engagement at ASH beyond their participation in the program, according to a ...

breast cancer
issues in oncology

Firefighters May Be Exposed to Chemicals Associated With Breast Cancer

Investigators have found that firefighters may face occupational exposures to multiple chemicals that could increase their risk of developing breast cancer, according to a recent study published by Cardona et al in Toxics. Background Prior research has revealed that firefighters have significantly...

hematologic malignancies

ASH to Present 2024 Honorific Awards at Annual Meeting

The American Society of Hematology (ASH) will recognize exemplary hematologists who have made significant contributions to the field with several honorific awards at the 2024 ASH Annual Meeting and Exposition, being held December 7–10 in San Diego. “ASH is honored to recognize these outstanding...

lymphoma

Determining the Optimal First-Line Management of Advanced Classical Hodgkin Lymphoma

“While clinical trials emphasize improvement in cure rates for patients with advanced classical Hodgkin lymphoma, an important goal is reducing the potential long-term effects of treatment,” commented Iris Isufi, MD, of the Smilow Cancer Hospital and Yale Cancer Center, New Haven, Connecticut, and ...

skin cancer
immunotherapy
issues in oncology

Immunotherapy Combination for Cutaneous Melanoma

Presurgical treatment with the novel drug vidutolimod and the PD-1 checkpoint inhibitor nivolumab may improve outcomes in patients with stage III cutaneous melanoma, according to a recent study published by Davar et al in Cancer Cell. The findings supported the development of vidutolimod for...

bladder cancer
prostate cancer
neuroendocrine tumors
immunotherapy

Pembrolizumab Plus Standard Chemotherapy May Benefit Patients With Rare, Aggressive Cancers

Researchers have found that combining the immunotherapy drug pembrolizumab with standard chemotherapy may improve treatment outcomes in patients with small cell bladder cancer and small cell/neuroendocrine prostate cancer, according to a recent study published by Gu et al in Cell Reports Medicine....

cns cancers

Study Finds In Situ Vaccination Using Tumor Treating Fields Plus Immune Checkpoint Inhibitors Extended Survival in Patients With Glioblastoma

A small study investigating tumor treating fields—an antimitotic electric fields therapy—in combination with pembrolizumab and temozolomide for the treatment of patients with glioblastoma was found to be a promising strategy, especially in patients with substantial residual tumor, according to the...

colorectal cancer
immunotherapy
issues in oncology

New Insights Into Innate Resistance for Immunotherapies in Colorectal Cancer

Researchers have assessed the efficacy of targeting the CD47 protein combined with traditional immunotherapy drugs in patients with colorectal cancer, with a recent study published by Arai et al in the Journal for ImmunoTherapy of Cancer. The findings indicated that the combination approach could...

solid tumors
cardio-oncology
covid-19

Study Explores Underpinnings of Immunotherapy-Releated Myocarditis in Patients With Cancer

Researchers may have uncovered the immune basis for the development of myocarditis in patients with cancer receiving immune checkpoint inhibitors, according to a recent study published by Blum et al in Nature. The findings revealed changes in specific types of immune and stromal cells in the heart...

leukemia
issues in oncology

Researchers May Have Uncovered Why Some AML Cells Resist Treatment

Researchers have provided new insights into acute myeloid leukemia (AML) and its resistance to venetoclax, according to a recent study published by Sango et al in Nature. Although AML is a rare disease, approximately 20,800 U.S. patients will be diagnosed in 2024, according to the American Cancer...

multiple myeloma

Evolving Role of MRD Status in Multiple Myeloma

The use of measurable (or minimal) residual disease (MRD) status to guide treatment in multiple myeloma has become a topic of intense interest. Phase III studies presented at the Plenary Session of the 2024 International Myeloma Society Annual Meeting moved MRD status ever closer to validation in...

skin cancer
immunotherapy
issues in oncology

Immunotherapy Combination May Demonstrate Benefit in Patients With Cutaneous Melanoma

Presurgical treatment with the novel drug vidutolimod and the PD-1 checkpoint inhibitor nivolumab may improve tumor control in patients with stage III cutaneous melanoma, according to a recent study published by Davar et al in Cancer Cell. The findings provided insights that could help advance...

solid tumors
hematologic malignancies
issues in oncology
genomics/genetics

Novel Method for Liquid Biopsies May Streamline Cancer Detection

Researchers have discovered a novel strategy to detect cancer cells with a liquid biopsy designed to be simpler, quicker, and more informational compared with current methods, according to a recent study published by Walker et al in Small. Background Current methods for detecting cancer cells may...

leukemia

Outcomes With Brexucabtagene Autoleucel as Standard Therapy for Adults With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

In an analysis reported in the Journal of Clinical Oncology, Roloff et al found that use of brexucabtagene autoleucel as standard therapy in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) was associated with a high rate of measurable residual disease (MRD)-negative...

colorectal cancer
issues in oncology

Weighing Blood-Based vs Standard Colorectal Cancer Screening Options

Because colonoscopies and more established stool-based tests are more effective at detecting early cancers and precancerous polyps compared with emerging blood-based tests, their long-term impact is projected to be substantially greater than that of blood-based tests, according to a recent study...

breast cancer
immunotherapy
issues in oncology

New Computational Tool May Predict Immunotherapy Outcomes in Patients With Metastatic Breast Cancer

Using computational tools, researchers have developed a novel method to assess which patients with metastatic triple-negative breast cancer may benefit from immunotherapy, according to a recent study published by Arulraj et al in the Proceedings of the National Academy of Sciences (PNAS)....

lung cancer

Use of Aumolertinib Extends Progression-Free Survival in Stage III EGFR-Mutated NSCLC

Aumolertinib, a third-generation EGFR tyrosine kinase inhibitor, has shown efficacy as maintenance therapy for patients with unresectable stage III non–small cell lung cancer (NSCLC) harboring EGFR mutations, according to data presented at the International Association for the Study of Lung Cancer...

gynecologic cancers

Addition of Cadonilimab to Platinum-Based Chemotherapy With or Without Bevacizumab in Cervical Cancer

In interim analyses of a Chinese phase III trial (COMPASSION-16) reported in The Lancet, Wu et al found that the addition of cadonilimab, a bispecific antibody targeting PD-1 and CTLA-4, to platinum-based chemotherapy with or without bevacizumab significantly improved progression-free and overall...

bladder cancer

Early Results Show Novel Agent Has Clinical Activity in FGFR3-Driven Advanced Bladder Cancer

In a phase I clinical trial (SURF301) investigating the fibroblast growth factor receptor 3 (FGFR3) oral inhibitor TYRA-300 in patients with advanced bladder cancer, the drug showed early antitumor activity and produced lower rates of significant adverse events compared with pan-FGFR inhibitors....

solid tumors
hematologic malignancies

National Academy of Medicine Elects 100 New Members

The National Academy of Medicine (NAM) announced the election of 90 regular members and 10 international members during its annual meeting. Background Established originally as the Institute of Medicine in 1970 by the National Academy of Sciences, NAM addresses critical issues in health, science,...

leukemia

New Directions in ALL, CML, and CLL Treatment

The Society of Hematologic Oncology (SOHO) 2024 Annual Meeting showcased several groundbreaking studies in the field of hematologic oncology, including key findings in childhood acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), and chronic lymphocytic leukemia (CLL). The ASCO...

hepatobiliary cancer
issues in oncology

Higher Dosage of Radioembolization With Y-90 Therapy May Improve Survival Rates and Facilitate Curative Treatment in Patients With Hepatocellular Carcinoma

Researchers found that a higher dosage of radioembolization treatment using yttrium (Y)-90 microspheres than previously recommended may benefit patients with hepatocellular carcinoma, according to a recent study published by Chen et al in Liver Cancer. The findings could be practice-changing....

prostate cancer

Can Blood Test Predict Survival in Metastatic Prostate Cancer?

A recent study found that measuring circulating tumor cells (CTCs) is a reliable way to predict later treatment response and survival prospects in men when metastatic prostate cancer is first diagnosed. The test may help providers to decide which patients should receive standard treatment vs who...

breast cancer
survivorship
genomics/genetics
issues in oncology

Common Breast Cancer Treatments May Speed Aging Process

Researchers have found that common breast cancer treatments—including chemotherapy, radiation, and surgery—may accelerate the biological aging process among breast cancer survivors, according to a new study published by Carroll et al in the Journal of the National Cancer Institute. The findings...

Advertisement

Advertisement




Advertisement